Jim Simons
ENGN icon

Jim Simons’s enGene Therapeutics ENGN Stock Holding History

Jim Simons’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
156,100
+135,318
+651% +$1.2M ﹤0.01% 2239
2025
Q4 		$188K Buy
+20,782
New +$167K ﹤0.01% 2901
2025
Q3 		– Sell
-11,400
Closed -$41.5K – 3599
2025
Q2 		$41.5K Buy
+11,400
New +$42.8K ﹤0.01% 3417

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Jim Simons's ENGN Position: Q1 2026 in Review

Jim Simons increased its enGene Therapeutics (ENGN) stake by 651% in Q1 2026, buying an estimated $1.2M and bringing the position to 156,100 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2239.

Jim Simons first reported a position in ENGN in Q2 2025 and has held it in 3 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Jim Simons held 156,100 shares of enGene Therapeutics worth $1.06M as of Q1 2026.
  • Jim Simons bought 135,318 enGene Therapeutics shares in Q1 2026, an estimated $1.2M.
  • enGene Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2239 holding.
  • Jim Simons first reported a position in enGene Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.